- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00287781
A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache
January 23, 2008 updated by: Kern Medical Center
Migraine headaches have previously been shown to be responsive to intranasal lidocaine in a small study.
Using a nebulizer to administer the drug would improve the feasibility of using the treatment.
It would also spare the patient narcotics with their attendant side effects.
Because of the potential for placebo effect a placebo control is necessary in this study.
Study Overview
Study Type
Interventional
Enrollment
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Bakersfield, California, United States, 93305
- Kern Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets IHS criteria for migraine
Exclusion Criteria:
- Pregnant
- Breast feeding
- Allergic to Lidocaine
- Worst or first Headache
- Abnormal neurological exam
- Substance abuse within 6 months
- Cardiac, liver or pulmonary disease
- Participation n another study within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Resolution of symptoms
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Improvement in 10 point pain score
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rick McPheeters, DO FAAEM, Kern Medical Center UCLA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2002
Study Completion
April 1, 2006
Study Registration Dates
First Submitted
February 6, 2006
First Submitted That Met QC Criteria
February 6, 2006
First Posted (Estimate)
February 7, 2006
Study Record Updates
Last Update Posted (Estimate)
January 25, 2008
Last Update Submitted That Met QC Criteria
January 23, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- #04028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.